Your browser doesn't support javascript.
SARS-CoV-2 Vaccination and the Bridge between First and Fourth Dose: Where Are We?
Stasi, Cristina; Meoni, Barbara; Voller, Fabio; Silvestri, Caterina.
  • Stasi C; Epidemiology Unit, Tuscany Regional Health Agency, Via Pietro Dazzi, 1, 50141 Florence, Italy.
  • Meoni B; MASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
  • Voller F; Center for Research and Innovation CRIA-MASVE, Careggi University Hospital, 50134 Florence, Italy.
  • Silvestri C; Epidemiology Unit, Tuscany Regional Health Agency, Via Pietro Dazzi, 1, 50141 Florence, Italy.
Vaccines (Basel) ; 10(3)2022 Mar 14.
Article in English | MEDLINE | ID: covidwho-1742764
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has induced the explosion of vaccine research. Currently, according to the data of the World Health Organization, there are several vaccines in clinical (145) and preclinical (195) stages, while at least 10 are already in clinical phase 4 (post-marketing). Vaccines have proven to be safe, effective, and able to reduce the spread of SARS-CoV-2 infection and its variants, as well as the clinical consequences of the development of coronavirus disease-19 (COVID-19). In the two-dose primary vaccination, different time intervals between the two doses have been used. Recently, special attention has been paid to assessing the immunogenicity following booster administration. The third dose of the vaccine against COVID-19 may be administered at least 8 weeks after the second dose. In Israel, a fourth dose has already been approved in immunocompromised groups. The main objective of this review is to describe the principal results of studies on the effectiveness of first-to-fourth dose vaccination to reduce reinfection by variants and the incidence of severe disease/death caused by COVID-19. Vaccines have shown a high level of protection from symptomatic infection and reinfection by variants after a third dose. Accelerating mass third-dose vaccination could potentially induce immunogenicity against variants.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10030444

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10030444